MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)

manilatimes.net · 2026-10-10

MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)

TickrTrends take: MannKind presented clinical data at HFSA 2026 regarding Furoscix ReadyFlow for managing edema in heart failure and chronic kidney disease patients, potentially expanding the commercial applications of its injectable furosemide platform. As a healthcare company currently valued as undervalued by TickrTrends, any expansion of Furoscix's addressable market through new clinical evidence could support stronger revenue trajectories that might justify higher valuations. Investors monitoring MNKD's valuation should track whether this data translates into regulatory approvals or payer coverage decisions that would meaningfully expand the patient population eligible for treatment.

Read the full story at manilatimes.net →